๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Non-specific and specific active immunotherapy in a B16 murine melanoma system

โœ Scribed by J. Avent; C. Vervaert; H. F. Seigler


Book ID
102924981
Publisher
John Wiley and Sons
Year
1979
Tongue
English
Weight
526 KB
Volume
12
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


Conflicts amongst reports concerning the efficacy of both nonspecific and specific attempts at immunotherapy may be ascribed to different animal models utilizing tumors of different immunogenicity. We have selected the B 16 mouse melanoma model as the example of a spontaneously occurring neoplasm that is histocompatible with the host and does have tunior-associated antigens. Attempts t o alter tumor growth or survival with nonspecific active imrnunotherapy as well as with specific active irnmunotherapy were not successful. Nonspecific active pre-iimnunization failed t o alter tumor take or growth. Specific active immunotherapy both with and without adjuvant did decrease tumor take and prolong host survival. The effects were increasingly documented at lower tumor cell inoculums and became less apparent with increase in the tumor cell challenge.


๐Ÿ“œ SIMILAR VOLUMES


A new approach in specific, active immun
โœ Dr. Marc K. Wallack; Zenon Steplewski; Hilary Koprowski; Ernest Rosato; Joan Geo ๐Ÿ“‚ Article ๐Ÿ“… 1977 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 447 KB ๐Ÿ‘ 2 views
A new model of active specific immunothe
โœ Moriguchi, Yoshio; Kan, Norimichi; Okino, Takashi; Harada, Takehisa; Yamasaki, S ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 716 KB

The possibility of active specific immunotherapy using interleukin-1 (IL-1) plus sonicated tumor supernatant (SS) was examined in a murine tumor model. The growth of intraperitoneally or subcutaneously inoculated plasmacytoma MOPC IME, which is syngeneic to BALB/c mice, was significantly suppressed

Active specific immunotherapy with polyv
โœ Eddy C. Hsueh; Larry Nathanson; Leland J. Foshag; Richard Essner; J. Anne Nizze; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 341 KB ๐Ÿ‘ 2 views

## BACKGROUND. This study was conducted to document the rate, duration, and type of objective response to active specific immunotherapy with a polyvalent melanoma cell vaccine (PMCV) for patients with in-transit melanoma metastases and to identify any acute or chronic toxic effects of PMCV treatme

Progress in active specific immunotherap
โœ Benjamin A. Tjoa; Gerald P. Murphy ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 124 KB ๐Ÿ‘ 2 views

Treatments available for metastatic prostate cancer have failed to demonstrate significant curative potential. Current efforts are now directed towards developments of novel strategies for the treatment of metastatic prostate cancer. Cancer immunotherapeutic strategies utilize patient immune system